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Glutamine metabolism, the Achilles heel
for medulloblastoma tumor
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Metabolic adaptation processes are believed to provide
cancer cells with proliferation and survival beneﬁts over
normal cells. However, these processes can also make
cancer cells selectively dependent, or addicted, to certain
nutrients and metabolic pathways, making tumor meta-
bolism an attractive therapeutic target1. One of these
addictions is the dependency on glutamine (Gln). Gluta-
mine is considered a semi-essential amino acid and,
typically, in the cell it can be synthetized from the
metabolism of other amino acids. Gln can be used for the
cells as a source of carbon and nitrogen. As well Gln
carbons can support anabolism by entering the tri-
carboxylic acid cycle (TCA) through glutaminolysis2. An
increased demand for Gln by cancer cells has been
recognized by researchers for almost a century3.
Speciﬁc tumor entities, such as MYC-overexpressing
liver tumor or p73-overexpressing medulloblastoma
tumors, exhibit Gln-dependency in vivo4,5. These ﬁndings
are in line with glutaminase inhibitors functioning as an
effective treatment for these tumors and a new generation
of glutaminase inhibitors are currently being tested in
clinical trials. It is commonly found that tumor cells
acquire Gln-dependency as an artifact of the culture
condition. Therefore, xenograft mouse models recapitu-
lating the tumor environment must be used to claim that
a tumor is “Gln-dependent”. Recently, Tardito et al. per-
formed an extensive study concluding that glioblastoma
multiforme (GBM) tumors are resistant to glutamine
deprivation, which clariﬁed recent controversial data
about Gln dependency in this type of tumors. This ﬁnding
could be related to the fact that, in vivo GBM tumors
relies on astrocytes and glioma cells as source of Gln6.
Together, all these data show that to label a tumor as
“Gln-dependent” we need to consider the cells of origin
and the genetic variations found in the tumor as previous
shown by Yuneva et al.7 The cell of origin is linked to the
pattern of metabolic enzymes expressed by the tumor. For
example, Gln and glutamate are essential amino acids
playing key roles in brain metabolism and function.
Indeed, in the brain, glutamine is the precursor of two
neurotransmitters, glutamate and GABA, promoting the
premise that brain tumors could be “Gln-dependent”.
Furthermore, the expression of different oncogenes is
also linked to the cellular metabolic landscape. For
example, MYC-overexpressing liver tumors will synthe-
tize high levels of glutaminase 1 enzyme (GLS-1) and will
have increased the degradation of glucose into lactate and
increased glutamine consumption through the TCA,
making these tumors “Gln-dependent” (Fig. 1). In con-
trast, MET-induced liver tumors utilize glucose to pro-
duce glutamine and therefore these tumors phenotype is
glutamine independent.
Medulloblastoma (MB) are the most common malig-
nant brain tumors in children and it is a major cause of
mortality and morbidity in pediatric oncology. Current
treatment include surgery, radiotherapy and chemother-
apy; they have achieved 70–80% 5-year survival rates,
however the treatment induces severe side effect. MB is a
heterogeneous tumor which consist of at least in four
distinct subgroups (Wingless [WNT], Sonic hedgehog
[SHH], group 3, and group 4), with unique molecular
signature, genetic mutation and clinical outcomes.
Recently, it has been suggested that MB could be addi-
tionally classiﬁed based on the presence of other muta-
tions, such as mutations in the TP53 gene. Indeed, the
presence of mutant p53 in SHH-MB is associated with a
poor outcome, in contrast mutation of p53 in WNT-MB
is a marker of good outcome8.
The prognostic value of TP53 in MBs promoted several
research groups to evaluate whether the other members of
the p53-family could also have a prognostic value. The
p53-family comprises three members: p53, p63 and p73.
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The role of this family in inducing apoptosis and senes-
cence has been extensively described9. Unlike p53, p73 is
frequently overexpressed in cancer. Accordingly, p73 is
overexpressed in aggressive MB (group 3 and 4) and was
shown to promote tumor cells growth and proliferation5.
Recently a new role for the p53-family in promoting cell
survival during metabolic stress was discovered. This
ﬁnding highlights on the role of p53-family in main-
tenance of the cellular energetic metabolism and the
redox state of the cell by regulating several metabolic
pathways such as glutamine metabolism (Fig. 1)10–12.
We investigate how p73 affect the metabolism of MB
tumors by using gene manipulation and metabolomics
analysis and we found that high p73 expression in MB
tumor cells is associated with Gln-dependency both
in vitro and in vivo. In line, we found that MB tumor cells
expressing p73 exhibit high expression of glutaminase 2
(GLS-2). This is linked to MB biology as when animals
were fed with a Gln-restriction diet, MB tumors growth
slowed down. More importantly, Gln-restriction diet
potentiated the anti-tumor activity of cisplatin (a che-
motherapeutic drug commonly used for MB patient
treatment), to reducing MB tumor growth and prolonging
survival of treated mice. The synergism that we found
between Gln-restriction diet and a chemotherapeutic
agent is exciting because it brings forth a possible less
toxic alternative treatment for MB patients.
The success of personalized medicine is dependent on
our ability to identify the Achilles heel of a particular
tumor. Indeed, “Gln-restriction diet or Gln-inhibitors”
are not suitable for treatment of every tumor. However,
as we increase our understanding of the particular roles
that glutamine plays in tumors cells and the role played
by speciﬁc genes, such as oncogenes, in glutamine
metabolism, we get ever closer to developing effective
targeted therapies based on the genetic landscape of the
tumor.
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Fig. 1 Metabolic pathways regulated by p73 or Myc in “Gln-dependent” tumors. Tumor cells expressing p73 or MYC will convert most glucose
to lactate and diverting glucose metabolites to support anabolic process to accelerate cell growth and proliferation. On the other hand, p73 or MYC
will stimulate the use of glutamine as a source of carbon for the TCA cycle and OXPHOS. GLS1 glutaminase 1, GLS2 glutaminase 2, GIn glutamine, Glu
glutamate, TCA tricarboxylic acid cycle, OXPHOS oxidative phosphorylation
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